Live
FierceBiotechChutes & Ladders—Former FDA leader takes new biotech TurnFierceBiotechASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancerEndpoints News#ASCO26: Merck partner Kelun outlines Phase 3 lung cancer success in China studyEndpoints News#ASCO26: Key head and neck cancer readouts from J&J, Corbus, Summit, Akero and BicaraEndpoints News#ASCO26: New data released for VEGF bispecifics from BioNTech-BMS, Pfizer-3SBioScienceAncient wars between microbes gave us key immune defensesClinical OMICsNext-Generation Cardiac AI System Outperforms Existing ModelsClinical OMICsOpen-Source Algorithm Advances Precision Menstrual Health Beyond FertilityEndpoints NewsHow a group of biotechs ran a covert campaign to push out the FDA commissionerClinical OMICsOncology’s Next AI Battleground: Instant Clinical and Commercial InsightBioWorldAppointments and advancements for May 21, 2026BioWorldFinancings for May 21, 2026
FierceBiotech Apr 6, 2026

March M&A surge triggers high expectations for 2026

March M&A surge triggers high expectations for 2026

Original
Body unavailable. Use the original source.